Also found in: Medical.
HDACHistone Deacetylase (biochemistry)
HDACHuntington's Disease Advocacy Center (Stanford, CA)
HDACHouse Democracy Assistance Commission (US House of Representatives)
HDACHydrogen/Deuterium Absorption Cell
HDACHuman Developmental Anatomy Center (National Museum of Health & Medicine; Washington, DC)
HDACHelen Day Art Center (Stowe, VT)
HDACHeavy Duty Air Cylinder
References in periodicals archive ?
An open beta service, trial test of the HDAC trading is set to begin Jan.
Additionally, PCM-075 synergy has been evaluated in combination with more than ten different chemotherapeutics used clinically for treatment of many solid and hematologic cancers, including cisplatin, cytarabine, doxorubicin, gemcitabine and paclitaxel, and targeted therapies, such as HDAC inhibitors, FLT3 inhibitors, and bortezomib.
sup][10],[11],[12] Emerging studies have revealed that HDAC inhibitors, such as suberoylanilide hydroxamic acid and trichostatin A (TSA), could alter MRP2 expression in tumor cells.
HBI-8000 is an orally bioavailable, low-nanomolar inhibitor of cancer-associated HDAC enzymes with favorable pharmacology and safety profiles.
Apparently, these HDAC inhibitors allow the brain to learn something, which it would be incapable of after reaching puberty.
Inhibitors of HDAC classes I and II are being studied as a treatment for cancer and neurodegenerative diseases such as Huntington's and Alzheimer's diseases.
This study provides further support for the relevance of SFN as a dietary HDAC inhibitor and chemopreventive agent by showing that SFN can selectively target BPH1, LnCap and PC3 prostate cells while leaving normal PrEC prostate cells virtually unaffected.
HDAC inhibitors are seen as a therapeutically important class of drugs, but the lack of specificity of the current generation of HDAC inhibitors has resulted in significant and often debilitating side-effects.
HDAC inhibitors can slow abnormal tumour cell growth, cause tumour cell death and correct abnormal cell differentiation in a wide range of cancers.
In addition to SB939, S*BIO's pipeline includes a portfolio of complementary HDAC inhibitors and two novel series of unique spectrum kinase inhibitors applicable for the treatment of both solid and hematological tumors.
HDAC is an enzyme that changes the way histones bind to the genes.
Eleven types of human HDAC were already known to occur in complex mixtures with related proteins, such as gene repressors and hormone receptors.